MAPT and Alzheimer disease: Despite extensive research identifying β-amyloid (Aβ) deposition in senile plaques and hyperphosphorylated Tau (pTau) in intracellular neurofibrillary tangles as key pathological markers of AD, approved treatments remain limited [3].